Protalix BioTherapeutics, Inc. (PLX) Free cash flow
- Free cash flow · 12 months (USD): Value $7.67M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 9.51%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $7.67M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $9.92M − $2.25M ≈ $7.67M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 9.51% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $7.67M ÷ $80.62M × 100 ≈ 9.51% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $9.92M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.52× | Operating cash flow / net income. Period ending 2026-06-30. $9.92M ÷ $18.95M ≈ 0.52× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 9.92M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 2.25M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 7.67M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 80.62M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 18.95M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.67M | (m) | $9.92M | $2.25M | (m) | $80.62M | (m) | $18.95M | (m) | (m) | 9.51% | 0.52× |
| 2026-03-31 | $13.00M | (m) | $15.09M | $2.09M | (m) | $76.38M | (m) | $15.33M | (m) | (m) | 17.02% | 0.98× |
| 2025-12-31 | $-13.63M | (m) | $-11.99M | $1.64M | (m) | $52.74M | (m) | $-6.60M | (m) | (m) | -25.84% | 1.82× |
| 2025-09-30 | $-11.69M | (m) | $-10.03M | $1.66M | (m) | $61.84M | (m) | $5.39M | (m) | (m) | -18.91% | -1.86× |
| 2025-06-30 | $-3.44M | (m) | $-2.19M | $1.25M | (m) | $61.95M | (m) | $6.28M | (m) | (m) | -5.56% | -0.35× |
| 2025-03-31 | $-1.56M | (m) | $-572.00K | $990.00K | (m) | $59.76M | (m) | $3.91M | (m) | (m) | -2.61% | -0.15× |
| 2024-12-31 | $7.39M | (m) | $8.67M | $1.28M | (m) | $53.40M | (m) | $2.93M | (m) | (m) | 13.84% | 2.96× |
| 2024-09-30 | $7.17M | (m) | $8.28M | $1.11M | (m) | $45.67M | (m) | $-9.61M | (m) | (m) | 15.70% | -0.86× |
| 2024-06-30 | $-4.18M | (m) | $-2.71M | $1.47M | (m) | $38.05M | (m) | $-14.69M | (m) | (m) | -10.99% | 0.18× |
| 2024-03-31 | $4.37M | (m) | $5.87M | $1.50M | (m) | $59.65M | (m) | $6.85M | (m) | (m) | 7.32% | 0.86× |
| 2023-12-31 | $-2.47M | (m) | $-1.32M | $1.15M | (m) | $65.49M | (m) | $8.31M | (m) | (m) | -3.77% | -0.16× |
| 2023-09-30 | $-8.64M | (m) | $-7.52M | $1.11M | (m) | $63.63M | (m) | $10.62M | (m) | (m) | -13.57% | -0.71× |
| 2023-06-30 | $-10.56M | (m) | $-9.84M | $723.00K | (m) | $67.46M | (m) | $8.90M | (m) | (m) | -15.66% | -1.11× |
| 2023-03-31 | $-22.82M | (m) | $-22.17M | $647.00K | (m) | $41.14M | (m) | $-15.77M | (m) | (m) | -55.46% | 1.41× |
| 2022-12-31 | $-25.63M | (m) | $-25.00M | $628.00K | (m) | $47.64M | (m) | $-14.93M | (m) | (m) | -53.80% | 1.67× |
| 2022-09-30 | $-28.34M | (m) | $-27.48M | $863.00K | (m) | $47.57M | (m) | $-17.85M | (m) | (m) | -59.57% | 1.54× |
| 2022-06-30 | $-21.30M | (m) | $-20.15M | $1.15M | (m) | $45.44M | (m) | $-18.49M | (m) | (m) | -46.88% | 1.09× |
| 2022-03-31 | $-7.58M | (m) | $-6.28M | $1.30M | (m) | $43.12M | (m) | $-24.39M | (m) | (m) | -17.59% | 0.26× |
| 2021-12-31 | $-11.74M | (m) | $-10.29M | $1.46M | (m) | $38.35M | (m) | $-27.58M | (m) | (m) | -30.62% | 0.37× |
| 2021-09-30 | $-14.03M | (m) | $-12.75M | $1.29M | (m) | $49.30M | (m) | $-20.52M | (m) | (m) | -28.47% | 0.62× |
| 2021-06-30 | $-15.52M | (m) | $-14.47M | $1.04M | (m) | $48.03M | (m) | $-20.76M | (m) | (m) | -32.30% | 0.70× |
| 2021-03-31 | $-29.80M | (m) | $-28.82M | $975.00K | (m) | $52.57M | (m) | $-13.66M | (m) | (m) | -56.68% | 2.11× |
| 2020-12-31 | $-26.76M | (m) | $-26.11M | $655.00K | (m) | $62.90M | (m) | $-6.52M | (m) | (m) | -42.55% | 4.00× |
| 2020-09-30 | $-22.65M | (m) | $-22.24M | $408.00K | (m) | $61.16M | (m) | $-6.63M | (m) | (m) | -37.03% | 3.36× |
| 2020-06-30 | $-22.56M | (m) | $-21.86M | $698.00K | (m) | $64.62M | (m) | $-5.75M | (m) | (m) | -34.91% | 3.80× |
| 2020-03-31 | $-19.72M | (m) | $-19.20M | $523.00K | (m) | $65.90M | (m) | $-9.35M | (m) | (m) | -29.93% | 2.05× |
| 2019-12-31 | $-19.98M | (m) | $-19.36M | $627.00K | (m) | $54.69M | (m) | $-18.28M | (m) | (m) | -36.54% | 1.06× |
| 2019-09-30 | $-20.46M | (m) | $-19.68M | $787.00K | (m) | (m) | (m) | $-24.00M | (m) | (m) | (m) | 0.82× |
| 2019-06-30 | $-3.31M | (m) | $-2.81M | $499.00K | (m) | (m) | (m) | $-25.76M | (m) | (m) | (m) | 0.11× |
| 2019-03-31 | $-6.21M | (m) | $-5.61M | $607.00K | (m) | (m) | (m) | $-26.48M | (m) | (m) | (m) | 0.21× |
| 2018-12-31 | $-8.43M | (m) | $-7.74M | $686.00K | (m) | (m) | (m) | $-26.46M | (m) | (m) | (m) | 0.29× |
| 2018-09-30 | $13.06M | (m) | $13.85M | $788.00K | (m) | $9.69M | (m) | $-51.38M | (m) | (m) | 134.81% | -0.27× |
| 2018-06-30 | $-11.15M | (m) | $-10.33M | $822.00K | (m) | $16.55M | (m) | $-47.27M | (m) | (m) | -67.34% | 0.22× |
| 2018-03-31 | $-11.98M | (m) | $-10.98M | $1.00M | (m) | $20.91M | (m) | $-35.53M | (m) | (m) | -57.31% | 0.31× |
| 2017-12-31 | $-10.96M | (m) | $-9.99M | $971.00K | (m) | $19.24M | (m) | $-85.28M | (m) | (m) | -56.98% | 0.12× |
| 2017-09-30 | $-35.72M | (m) | $-34.92M | $798.00K | (m) | $18.85M | (m) | $-72.76M | (m) | (m) | -189.46% | 0.48× |
| 2017-06-30 | $-28.64M | (m) | $-27.83M | $817.00K | (m) | $16.00M | (m) | $-68.61M | (m) | (m) | -179.04% | 0.41× |
| 2017-03-31 | $-31.72M | (m) | $-30.90M | $818.00K | (m) | $11.41M | (m) | $-79.92M | (m) | (m) | -278.00% | 0.39× |
| 2016-12-31 | $-32.95M | (m) | $-32.10M | $849.00K | (m) | $9.20M | (m) | $-29.36M | (m) | (m) | -358.16% | 1.09× |
| 2016-09-30 | $-29.35M | (m) | $-28.62M | $736.00K | (m) | $7.12M | (m) | $46.16M | (m) | (m) | -412.38% | -0.62× |
| 2016-06-30 | $-34.54M | (m) | $-33.83M | $707.00K | (m) | $3.78M | (m) | $49.63M | (m) | (m) | -912.82% | -0.68× |
| 2016-03-31 | $-28.10M | (m) | $-27.49M | $616.00K | (m) | $3.35M | (m) | $55.41M | (m) | (m) | -838.68% | -0.50× |
| 2015-12-31 | $-24.75M | (m) | $-24.28M | $464.00K | (m) | $4.36M | (m) | $58.04M | (m) | (m) | -567.09% | -0.42× |
| 2015-09-30 | $-25.93M | (m) | $-25.30M | $628.00K | (m) | (m) | (m) | $-23.33M | (m) | (m) | (m) | 1.08× |
| 2015-06-30 | $-26.93M | (m) | $-26.19M | $746.00K | (m) | $12.70M | (m) | $-27.52M | (m) | (m) | -212.02% | 0.95× |
| 2015-03-31 | $-27.98M | (m) | $-27.36M | $621.00K | (m) | $11.35M | (m) | $-28.57M | (m) | (m) | -246.61% | 0.96× |
| 2014-12-31 | $-30.07M | (m) | $-29.28M | $785.00K | (m) | $13.65M | (m) | $-29.94M | (m) | (m) | -220.25% | 0.98× |
| 2014-09-30 | $-29.99M | (m) | $-29.15M | $839.00K | (m) | $13.88M | (m) | $-32.36M | (m) | (m) | -216.05% | 0.90× |
| 2014-06-30 | $-28.74M | (m) | $-27.82M | $920.00K | (m) | $13.77M | (m) | $-30.10M | (m) | (m) | -208.72% | 0.92× |
| 2014-03-31 | $-30.92M | (m) | $-29.41M | $1.51M | (m) | $13.61M | (m) | $-30.81M | (m) | (m) | -227.22% | 0.95× |
| 2013-12-31 | $-32.54M | (m) | $-30.65M | $1.89M | (m) | $10.48M | (m) | $-27.79M | (m) | (m) | -310.55% | 1.10× |
| 2013-09-30 | $-26.01M | (m) | $-24.09M | $1.92M | (m) | $9.29M | (m) | $-26.78M | (m) | (m) | -280.03% | 0.90× |
| 2013-06-30 | $-26.27M | (m) | $-23.90M | $2.36M | (m) | $10.73M | (m) | $-26.51M | (m) | (m) | -244.83% | 0.90× |
| 2013-03-31 | $-4.57M | (m) | $-2.67M | $1.90M | (m) | $34.58M | (m) | $-10.04M | (m) | (m) | -13.22% | 0.27× |
| 2012-12-31 | $-1.43M | (m) | $635.00K | $2.07M | (m) | $34.87M | (m) | $-11.62M | (m) | (m) | -4.11% | -0.05× |
| 2012-09-30 | $-10.32M | (m) | $-7.80M | $2.52M | (m) | $36.06M | (m) | $-10.65M | (m) | (m) | -28.62% | 0.73× |
| 2012-06-30 | $-10.65M | (m) | $-7.92M | $2.74M | (m) | $33.47M | (m) | $-14.05M | (m) | (m) | -31.83% | 0.56× |
| 2012-03-31 | $-29.77M | (m) | $-25.86M | $3.91M | (m) | $8.12M | (m) | $-37.38M | (m) | (m) | -366.72% | 0.69× |
| 2011-12-31 | $-29.27M | (m) | $-23.57M | $5.71M | (m) | $8.39M | (m) | $-36.53M | (m) | (m) | -349.09% | 0.65× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-46.32M | (m) | $-38.46M | $7.86M | (m) | $6.64M | (m) | $-29.00M | (m) | (m) | -697.37% | 1.33× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $38.26M | (m) | $44.45M | $6.20M | (m) | $388.00K | (m) | $-31.44M | (m) | (m) | 9860.05% | -1.41× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |